Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis

New England Journal of Medicine

Volumn 352, Issue 13, 2005, Pages

  Chimowitz, Marc I ^a,j   Lynn, Michael J ^b   Howlett Smith, Harriet ^a   Stern, Barney J ^a   Hertzberg, Vicki S ^b   Frankel, Michael R ^a   Levine, Steven R ^c   Chaturvedi, Seemant ^d   Kasner, Scott E ^e   Benesch, Curtis G ^f   Sila, Cathy A ^g   Jovin, Tudor G ^h   Romano, Jose G ⁱ  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^j EMORY CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; STATINE DERIVATIVE; WARFARIN;

AORTA ANEURYSM; ARTICLE; BRAIN ANGIOGRAPHY; BRAIN HEMORRHAGE; CANCER; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; DYSPEPSIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HAZARD ASSESSMENT; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RISK BENEFIT ANALYSIS; SEPSIS; SIDE EFFECT; STROKE; SUBDURAL HEMATOMA; SUDDEN DEATH; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ADULT; AGED; ANTICOAGULANTS; ASPIRIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; MORTALITY; RECURRENCE; WARFARIN;

EID: 20144366696     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa043033     Document Type: Article

References (41)

1. Wityk RJ, Lehman D, Klag M, Coresh J, Ahn H, Litt B. Race and sex differences in the distribution of cerebral atherosclerosis. Stroke 1996;27:1974-80.
2. Feldmann E, Daneault N, Kwan E, et al. Chinese-white differences in the distribution of occlusive cerebrovascular disease. Neurology 1990;40:1541-5.
3. Sacco RL, Kargman DE, Gu Q, Zamanillo MC. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction: the Northern Manhattan Stroke Study. Stroke 1995;26:14-20.
4. Broderick J, Brott T, Kothari R, et al. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke 1998;29:415-21.
5. Johnston SC. Transient ischemic attack. N Engl J Med 2002;347:1687-92.
6. Chimowitz MI, Kokkinos J, Strong J, et al. The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology 1995;45:1488-93.
7. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group. Prognosis of patients with symptomatic vertebral or basilar artery stenosis. Stroke 1998;29:1389-92.
8. Millikan CH, Siekert RG, Shick RM. Studies in cerebrovascular disease. III. The use of anticoagulant drugs in the treatment of insufficiency or thrombosis within the basilar arterial system. Mayo Clin Proc 1955;30:116-26.
9. Thijs VN, Albers GW. Symptomatic intracranial atherosclerosis: outcome of patients who fail antithrombotic therapy. Neurology 2000;55:490-7.
10. Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-51.
11. Chimowitz MI, Williams J, Stern BJ, et al. Physician preferences for diagnosis and treatment of symptomatic intracranial arterial stenosis. Neurology 2004;62:Suppl 5: A266-A267.
12. Benesch CG, Chimowitz MI. Best treatment for intracranial arterial stenosis? 50 Years of uncertainty. Neurology 2000;55:465-6.
13. The Warfarin Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Design, progress and challenges of a double blind trial of warfarin versus aspirin for symptomatic intracranial arterial stenosis. Neuroepidemiology 2003;22:106-17.
14. Samuels OB, Joseph GJ, Lynn MJ, Smith HA, Chimowitz MI. A standardized method for measuring intracranial stenosis. AJNR Am J Neuroradiol 2000;21:643-6.
15. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage: facts and theories. Stroke 1995;26:1471-7.
16. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980:163-78.
17. DeMets DL, Lan KKG. Interim analysis: the alpha spending function approach. Stat Med 1994;13:1341-52.
18. Lan KKG, Wittes J. The B-value: a tool for monitoring data. Biometrics 1988;44:579-85.
19. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-9.
20. Chan AT. Aspirin, non-steroidal anti-inflammatory drugs and colorectal neoplasia: future challenges in chemoprevention. Cancer Causes Control 2003;14:413-8.
21. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 1998;114: Suppl:579S-589S.
22. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-91.
23. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-74.
24. van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002;360:109-13.
25. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331-6.
26. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004;35:175-8.
27. Ratnatunga CP, Edmondson SF, Rees GM, Kovacs IB. High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation. Circulation 1992;85:1077-82.
28. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9. [Erratum, N Engl J Med 1997;337:356.]
29. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9. [Erratum, N Engl J Med 1997;337:356.]
30. Kharbanda RK, Walton B, Allen M, et al. Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation 2002;105:2600-4.
31. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:Suppl:204S-233S.
32. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-75.
33. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995;273:1421-8.
34. Barnett HJM, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med 1998;339:1415-25.
35. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
36. Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004;291:576-84.
37. Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003;289:2947-57.
38. Urbano LA, Bogousslavsky J. Antiplatelet drugs in ischemic stroke prevention: from monotherapy to combined treatment. Cerebrovasc Dis 2004;17:Suppl 1:74-80.
39. Gomez CR, Orr SC. Angioplasty and stenting for primary treatment of intracranial arterial stenoses. Arch Neurol 2001;58:1687-90.
40. Chimowitz MI. Angioplasty or stenting is not appropriate as first-line treatment of intracranial stenosis. Arch Neurol 2001;58:1690-2.
41. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995;274:1839-45.